Loading
RP
RVL Pharmaceuticals plc Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Burgstahler David F, was filed 09 Aug 2022.
RVL Pharmaceuticals plc: what insiders have been doing
This page follows insider dealings at RVL Pharmaceuticals plc as filed with SEC (Form 4), a company from the Healthcare & Pharma sector. RVL Pharmaceuticals plc has had no insider filing for more than a year; the last one goes back to 23 October 2023.
Looking back to 2019, when coverage begins, insiders filed 5 purchases and 3 sales.
For comparison within the same sector, see the insider buying recorded at Dynavox Group AB and EssilorLuxottica. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
79
Thresholds
n/a
Buy Volume
€19M
5 ops. · all time
Sell Volume
€757,743
3 ops. · all time
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2022FY ended December 2022 · cache
Income statement
RevenueUS$42.8M
Gross profitUS$34.7M81% margin
Net income-US$44.5M-104.0% margin
Last declaration on 23 October 2023
Declarations79 total
4,758,899 shares@ US$0.03122.3% of flowOrdinary SharesSEC:0001754526-23-000002:1
4,758,899 shares@ US$0.03122.3% of flowOrdinary SharesSEC:0001752864-23-000002:1
9,363,760 shares@ US$0.046166.0% of flowOrdinary SharesSEC:0001754526-23-000002:0
9,363,760 shares@ US$0.046166.0% of flowOrdinary SharesSEC:0001752864-23-000002:0
3,421,537 shares@ US$0.064634.0% of flowOrdinary SharesSEC:0001752864-23-000001:0
3,421,537 shares@ US$0.064634.0% of flowOrdinary SharesSEC:0001754526-23-000001:0
23,730,864 sharesOrdinary SharesSEC:0001104659-23-093104:0
12,000 shares@ US$0.49100.0% of flowOrdinary SharesSEC:0001104659-23-091548:0
40,000 shares0Ordinary SharesSEC:0001104659-23-080117:0
40,000 shares0Ordinary SharesSEC:0001104659-23-080118:0
40,000 shares0Ordinary SharesSEC:0001104659-23-080116:0
5,447 shares@ US$0.8713.2% of flowOrdinary SharesSEC:0001104659-23-063321:0
5,577 shares@ US$0.871.7% of flowOrdinary SharesSEC:0001104659-23-063324:0
1,032,995 shares0Ordinary SharesSEC:0001104659-23-008075:0
1,032,995 shares0Ordinary SharesSEC:0001104659-23-008079:0
1,032,995 shares0Ordinary SharesSEC:0001104659-23-008077:0
9,608 shares@ US$1.264.3% of flowOrdinary SharesSEC:0001104659-23-007068:0
9,608 shares@ US$1.2633.4% of flowOrdinary SharesSEC:0001104659-23-007069:0
75,000 shares0Ordinary SharesSEC:0001104659-22-090049:0
8,000,000 shares@ US$1.55100.0% of flowOrdinary SharesSEC:0001104659-22-088033:0
Canonical exit: 6 Nov 2022 (T+90)
8,000,000 shares@ US$1.55100.0% of flowOrdinary SharesSEC:0001104659-22-088030:0
Canonical exit: 6 Nov 2022 (T+90)
850,000 shares@ US$1.55100.0% of flowOrdinary SharesSEC:0001104659-22-088034:0
Canonical exit: 6 Nov 2022 (T+90)
150,000 shares@ US$1.5587.2% of flowOrdinary SharesSEC:0001104659-22-088038:0
Canonical exit: 6 Nov 2022 (T+90)
▲
Same trade as the filing by David F. Burgstahler, counted once
12M USD28SEC
8,000,000 shares@ US$1.55100.0% of flowOrdinary SharesSEC:0001104659-22-088025:0
Canonical exit: 6 Nov 2022 (T+90)
5,447 shares@ US$1.4043.2% of flowOrdinary SharesSEC:0001104659-22-063394:0
25 of 79 declarations
About RVL Pharmaceuticals plc
RVL Pharmaceuticals plc is a specialty pharmaceutical company that was listed on the U.S. NASDAQ market and operated from the United States, with principal business activities centered in Bridgewater, New Jersey. The company’s commercial identity was built around underserved therapeutic niches in ocular medicine and medical aesthetics, and its best-known asset was UPNEEQ® (oxymetazoline hydrochloride ophthalmic solution) 0.1%, a prescription treatment for acquired blepharoptosis, or droopy eyelid, in adults. RVL’s model combined product commercialization with tech-enabled access and integrated fulfillment designed to support both clinicians and patients. ([rvlpharma.com](https://www.rvlpharma.com/about-us?utm_source=openai))
From a historical standpoint, RVL Pharmaceuticals plc was organized as an Irish public limited company while its operating footprint was primarily U.S.-based. SEC filings identified Bridgewater, New Jersey, as the company’s principal executive office, and earlier filings also referenced a New Jersey pharmacy operation in Sayreville that supported the Upneeq supply and distribution chain. This structure is important for investors because it highlights a company incorporated outside the United States but commercially anchored in the U.S. market. ([ir.rvlpharma.com](https://ir.rvlpharma.com/company-profile?utm_source=openai))
Read moreShow less
RVL’s core business was that of a focused specialty pharma company rather than a broad diversified pharmaceutical platform. Its strategy relied on a narrow portfolio built around a flagship brand, with Upneeq serving as the main value driver. The company targeted physicians and aesthetic practices that treat eyelid ptosis and related cosmetic or functional concerns, aiming to differentiate itself through a category-creating product, specialized commercial execution, and patient-access tools. In competitive terms, RVL operated in a niche where clinical differentiation, regulatory positioning, and sales-force execution mattered more than scale. ([rvlpharma.com](https://www.rvlpharma.com/about-us?utm_source=openai))
The most material recent development was financial distress and restructuring. In 2023, RVL’s U.S. operating subsidiaries entered Chapter 11 proceedings, and SEC disclosures stated that the former public parent RVL Pharmaceuticals plc was expected to be wound down, with public equity cancellation anticipated and no recovery for ordinary shareholders. For market participants, that is a critical point: even if the company name still appears in historical market data or corporate references, the equity story was effectively transformed by the restructuring process. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1739426/000110465923121234/tm2331439d1_8k.htm?utm_source=openai))
In summary, RVL Pharmaceuticals plc should be viewed as a U.S.-operating, NASDAQ-listed specialty pharma company built around Upneeq, with a concentrated product profile, a Bridgewater, New Jersey headquarters, and a recent corporate history dominated by restructuring rather than growth. For French-speaking investors, the key takeaway is that the company’s commercial narrative is straightforward, but its capital structure and public-shareholder outcome were materially affected by the 2023 reorganization and wind-down process. ([ir.rvlpharma.com](https://ir.rvlpharma.com/news-releases/rvl-pharmaceuticals-plc-announces-prepackaged-reoganization-of-certain-us-subsidiaries?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
